We need stronger evidence for (or against) hepatocellular carcinoma surveillance

Jepsen, Peter; West, Joe

Abstract

Current guidelines from EASL recommend that most patients with cirrhosis are offered surveillance for hepatocellular carcinoma (HCC), but fewer than expected patients actually receive it. The recommendation is based on observational studies and simulations, not randomized trials. In this opinion piece we argue that a randomized trial of HCC surveillance vs. no surveillance is necessary and feasible, and we believe that clinician and patient participation in HCC surveillance would be better if it were based on trial results demonstrating its value.

Citation

Jepsen, P., & West, J. (2021). We need stronger evidence for (or against) hepatocellular carcinoma surveillance. Journal of Hepatology, 74(5), 1234-1239. https://doi.org/10.1016/j.jhep.2020.12.029

• Journal Article Type: Article
• Acceptance Date: Dec 23, 2020
• Online Publication Date: Jan 17, 2021
• Publication Date: May 1, 2021
• Deposit Date: Feb 10, 2021
• Publicly Available Date: Jan 18, 2022
• Journal: Journal of Hepatology
• Print ISSN: 0168-8278
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 74
• Issue: 5
• Pages: 1234-1239
• DOI: https://doi.org/10.1016/j.jhep.2020.12.029
• Keywords: Hepatology
• Public URL: https://nottingham-repository.worktribe.com/output/5262630
• Publisher URL: https://www.journal-of-hepatology.eu/article/S0168-8278(21)00020-9/fulltext
• Related Public URLs: https://www.sciencedirect.com/science/article/pii/S0168827821000209